An international pilot that allowed companies to have their applications for increasing drug manufacturing capacity to be simultaneously evaluated by multiple regulatory authorities has yielded positive results for industry and is to be continued throughout 2025.
Global Pilot Reduces Drug Manufacturing Inspections With Hybrid Approach
A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.
More from Manufacturing
• By
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.
• By
A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.
More from Geography
• By
The loss of policy analyst, legal, project manager and social scientist positions has experts wondering if the Trump Administration is eyeing a broader effort to limit DTC advertising. The OPDP layoffs are expected to result in delayed reviews of promotional pieces.
• By
In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.
• By
CMED, which sets medicine prices in Brazil, has published the maximum price adjustment index for 2025.